BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026

BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026.

PRNewsWire • Feb 17, 2026

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market

BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

PRNewsWire • Feb 12, 2026

4 Medical Product Stocks to Watch From a Challenging Industry (Revised)

The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Zacks Investment Research • Feb 3, 2026

4 Medical Product Stocks to Watch From a Challenging Industry

The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Zacks Investment Research • Feb 2, 2026

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations

Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million exceeded the high end of the previously raised guidance range for FY 2025 BOTHELL, Wash., Jan. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc.  (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.

PRNewsWire • Jan 12, 2026

BioLife Solutions' CFO Sells 30,000 Shares

The CFO sold 30,000 shares for $771,600. This transaction represented 16.4% of Wichterman's direct holdings, reducing his direct stake to 152,769 shares.

The Motley Fool • Dec 11, 2025

BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence

New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , Nov. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J.

PRNewsWire • Nov 20, 2025

BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025

BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December: Raymond James Napa Small Cap Symposium November 17, 2025 Napa Valley at The Meritage Stephens Annual Investment Conference November 18-20, 2025 Nashville at the Grand Hyatt Nashville Jefferies Global Healthcare Conference November 17-20, 2025 London at The Waldorf Hilton Furey Research Partners Hidden Gems Conference November 24-25, 2025 Virtual Wolfe Research Small & Mid-Cap Conference December 2-3, 2025 Virtual Northland Growth Conference 2025 December 16, 2025 Virtual The BioLife Solutions Investor Presentation, reflecting the recently refreshed corporate branding, is now available on the Investor Relations section of the company's website.

PRNewsWire • Nov 17, 2025

New Strong Buy Stocks for November 10th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Investment Research • Nov 10, 2025

BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript

BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call.

Seeking Alpha • Nov 7, 2025